|
Summary of Age and Doses used in clinical trials by type of therapy(mg/kg) |
||||
| Treatment group |
Median age, years (range) |
Dose(mg/kg) at Initiation of therapy (mean ± SD) |
Total dose over first 12 hours (mg/kg) (mean ± SD) |
Total dose over first 24 hours (mg/kg) (mean ± SD) |
|
|
||||
| Artemether ir*, single dose |
2.08 (0.42 – 5) |
6.7 ± 1.19 |
6.7 ± 1.19 |
6.7 ± 1.19 |
| Artemisinin ir, single dose |
19 (4 – 41) |
20.0 ± 0 |
20.0 ± 0 |
20.0 ± 0 |
| Artemisinin ir, multiple dose |
20 (0.7 – 62) |
31.5 ± 8 |
45.1 ± 14 |
45.1 ± 14 |
| Artesunate ir, multiple dose |
19 (1.3 – 80) |
6.65 ± 4 |
8.1 ± 4.17 |
14.8 ± 7.64 |
| Artesunate ir, single dose – 10 mg/kg |
12 (1.33 – 58) |
9.4 ± 2.47 |
9.4 ± 2.47 |
9.4 ± 2.53 |
| Artesunate per os |
6 (0.92 – 15) |
4.0 ± 0 |
4.0 ± 0 |
4.0 ± 0 |
| Artemisinins parenteral |
18 (0.5 – 66) |
2.94 ± 0.61 |
2.94 ± .0.6 |
3.43 ± 0.99 |
| Quinine parenteral |
3 (0.3 – 49) |
17.6 ± 4.31 |
24.2 ± 4.96 |
36.6 ± 5.7 |
| Quinine parenteral + Artesunate ir |
45 (32 – 60) |
- |
- |
- |
| Artesunate ir, single – 20 mg/kg |
6.3 (2 – 30) |
19.4 ± 1.63 |
19.4 ± 1.63 |
20.7 ± 0.99 |
|
* ir: Intra-rectal | ||||
Gomes et al. BMC Infectious Diseases 2008 8:39 doi:10.1186/1471-2334-8-39 |
||||